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Background: Malignant pleural mesothelioma (MPM) often develops decades following exposure to asbestos.
Current best therapy produces a response in only half of patients, and the median survival with this therapy
remains under a year. A search for novel targets and therapeutics is underway, and recently identified targets
include VEGF, Notch, and EphB4-Ephrin-B2. Each of these targets has dual activity, promoting tumor cell growth as
well as tumor angiogenesis.
Methods: We investigated EphB4 expression in 39 human mesothelioma tissues by immunohistochemistry.
Xenograft tumors established with human mesothelioma cells were treated with an EphB4 inhibitor (monomeric
soluble EphB4 fused to human serum albumin, or sEphB4-HSA). The combinatorial effect of sEphB4-HSA and
biologic agent was also studied.
Results: EphB4 was overexpressed in 72% of mesothelioma tissues evaluated, with 85% of epithelioid and 38% of
sarcomatoid subtypes demonstrating overexpression. The EphB4 inhibitor sEphB4-HSA was highly active as a single
agent to inhibit tumor growth, accompanied by tumor cell apoptosis and inhibition of PI3K and Src signaling.
Combination of sEphB4-HSA and the anti-VEGF antibody (Bevacizumab) was superior to each agent alone and led
to complete tumor regression.
Conclusion: EphB4 is a potential therapeutic target in mesothelioma. Clinical investigation of sEphB4-HSA as a
single agent and in combination with VEGF inhibitors is warranted.
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Malignant pleural mesothelioma (MPM) is a uniformly
fatal disease. It originates from normal mesothelial cells
lining the pleural or peritoneal cavity long after exposure
to asbestos [1,2]. There are three main histological types
of malignant mesothelioma (epitheloid, sarcomatoid, and
mixed or biphasic), with longer survival in epitheloid
and shorter survival in sarcomatoid types [3]. Nearly
3,000 new cases are diagnosed each year in the United
States [2]. The median overall survival of MPM patients
ranges from 12 to 24 months [3].
The most effective treatment regimen (cisplatin and
pemetrexed) induces partial response in half of patients
and improves survival from 9 to 12 months [4]. Novel* Correspondence: parkashg@usc.edu; valery@vasgene.com
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reproduction in any medium, provided the ortargeted therapies have been investigated in MPM with
limited success, including vascular endothelial growth
factor (VEGF) inhibitors [5,6]. Discovery of additional
targets and rational combinations of targeted therapies
may lead to effective novel therapies. The type 1 recep-
tor tyrosine kinase EphB4 and its cognate ligand Ephrin-
B2 are a pair of potential novel targets.
EphB4 and Ephrin-B2 are normally expressed on en-
dothelial cells of venous and arterial lineage, respectively,
and their interaction is critically required for new vessel
formation, fusion between vessel compartments, and
blood flow [7,8]. In addition, Ephrin-B2 is also expressed
on pericytes and vascular smooth muscle cells, where it
plays critical role in vessel maturation [9,10]. In tumor
angiogenesis, loss of Ephrin-B2 leads both to signifi-
cantly reduced tumor vessel density and to tumor growth
[11-14]. EphB4, on the other hand, is overexpressed in a
variety of epithelial cancers, including breast, prostate,
ovarian, esophageal, colon, and head and neck cancers
[15-23]. Importantly, we have also shown that EphB4 isThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tage to tumor cells [24].
Both EphB4 and Ephrin-B2 are transmembrane pro-
teins and direct cell-cell contact leads to bidirectional
signaling. EphB4 activation leads to downstream activa-
tion of the phosphoinositide kinase-3 (PI3K) pathway in
tumor cells [20], while Ephrin-B2 activation leads to ac-
tivation of Src [25,26]. Inhibition of EphB4-Ephrin-B2
signaling blocks tumor angiogenesis, which in turn leads
to hypoxia and induces VEGF expression [14]. Targeting
VEGF and EphB4-Ephrin-B2 simultaneously is thus a
potentially effective therapy.
In this study, we investigated the aberrant expression
of EphB4 in a cohort of primary MPM tissues. We show
that a significant proportion of MPM tumors expressed
EphB4, which provides survival advantage to tumor cells.
We also investigated the efficacy of sEphB4-HSA as an
inhibitor of EphB4-Ephrin-B2 in MPM xenograft mo-
dels. sEphB4-HSA induces cell death in MPM tumor
xenografts in vivo and down-regulates major signaling
pathways including PI3K and Src. In addition, we de-
monstrate that the combination of sEphB4-HSA and
VEGF antibody has superior efficacy than either single
agent alone, leading to complete tumor regression. Based
on these promising preclinical results, future clinicalFigure 1 EphB4 overoverexpression in MPM. (A) A panel of MPM tissues
expression level was scored and summarized. Moderate and strong expressio
demonstrating EphB4 expression patterns in epithelioid and sarcomatoid sub
with human EphB4 overexpresion vector or empty vector pCDNA3.1. 2 days a
with MAb131 that was also used for staining in (A). Nuclei were counter-staininvestigation of the efficacy of sEphB4-HSA combined
with VEGF inhibitors in MPM is warranted.Methods
Materials
Soluble EphB4 cDNA fused in-frame with human serum
albumin cDNA [14] was expressed as a seamless fusion
protein in CHO cells and purified to homogeneity.
EphB4-specific antibody (MAb131) was produced by
VasGene Therapeutics Inc. Bevacizumab (Genentech
Inc) was purchased. Phosphorylated AKT (Ser473), S6
(Ser235/Ser236) and Src (Tyr416) antibodies were from
Cell Signaling, Ki67 antibody was from Abcam, CD31
and NG2 antibodies were from BD Biosciences, and ter-
minal deoxynucleotidyl transferase–mediated dUTP nick
end labeling (TUNEL) fluorescent kit was from Promega.Cell lines
NCI-H2373 and MSTO-211H mesothelioma cell lines
were obtained from American Type Culture Collection
(Manassas, VA). Cells were maintained in RPMI 1640
supplemented with 10% heat-inactivated fetal bovine
serum (FBS; Life Technologies, Gaithersburg, MD) and
penicillin/streptomycin (Invitrogen, Carlsbad, CA).was stained with EphB4-specific antibody MAb131, and EphB4
n was considered overexpression. (B) Representative images
types. (C) 293T cells grown on 8-well chamber slide were transfected
fter transfection, cells were fixed with 4% paraformaldehyde and stained
ed with DAPI.
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Formalin-fixed paraffin-embedded malignant mesothe-
lioma tumors were analyzed. Tissue analysis was ap-
proved by the institutional review board. 4-μm sections
were deparaffinized, rehydrated, and washed with TBS/
Tween-20. Antigens were retrieved with exposure to 1
mM EDTA (pH 8.0; DakoCytomation) for 20 minutes.
Endogenous peroxidase activity in samples was blocked
by exposure to 3% hydrogen peroxide/PBS (Fisher Scien-
tific, Fair Lawn, NJ) and serum-free protein block
(DakoCytomation). Tissue sections were incubated with
primary antibodies overnight at 4°C. Standard avidin/
biotin immunoperoxidase methods with diaminoben-
zidines as the chromogen were used for detectionFigure 2 sEphB4-HSA inhibited proliferation and induced apoptosis o
profoundly inhibited H2373 tumor growth in vivo. (B) Representative image
reduced vessel density and tumor cell proliferation by sEphB4-HSA treatme
(C) Representative images of TUNEL staining of harvested H2373 tumors sh
coverage was normalized to DAPI coverage. (D) Representative images of p
showing inhibited PI3K and Src signaling by sEphB4-HSA treatment. At leas
statistical analysis. *, P<0.01; **, P<0.002. Error bars indicate standard error o(DakoCytomation). The intensity of staining was quan-
tified with ImageJ (NIH). EphB4-specific monoclonal
mouse anti-human antibody MAb131 was used for MPM
tissues. Positive controls included the 293T cell line stably
expressing full-length EphB4. Negative controls included
co-incubation of tissues with primary antibody and im-
munizing peptide.
In vivo tumor growth studies
Male BALB/c nu/nu mice (9 weeks old) were injected
with 5 × 106 tumor cells in the flank. When tumor sizes
reached 150 mm3, mice were grouped (8 tumors per
group) and treated with intraperitoneal (i.p.) injection of
PBS (control, 3 times per week), sEphB4-HSA (20 mg/kg,f MPM cell in vivo. (A) sEphB4-HSA (20 mg/kg, 3 times a week)
s of CD31 and Ki67 staining of harvested H2373 tumors showing
nt. CD31 and Ki67 coverage were normalized to DAPI coverage.
owing induced tumor cell apoptosis by sEphB4-HSA treatment. TUNEL
hosphorylated Akt, S6, and Src staining of harvested H2373 tumors
t 4 images from each analysis were used for quantification and
f mean.
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or a combination of sEphB4-HSA and Bevacizumab. Tu-
mor volume was measured three times a week and calcu-
lated using the following formula: tumor volume = 0.52 ×
length × width2, where length and width are the longest
and shortest dimensions of a palpable tumor. All proce-
dures were approved by Institutional Animal Care and
Use Committee and performed in accordance with the
Animal Welfare Act regulations.Immunofluorescence
Xenograft tumors were harvested and immediately snap
frozen. 5-μm fresh frozen tissue sections were fixed in
phosphate-buffered 4% paraformaldehyde, blocked with
goat serum, and incubated with primary antibody over-
night at 4°C. Antibody binding was localized with ap-
propriate AlexaFluor-conjugated secondary antibodies
(Invitrogen, Carlsbad, CA). Nuclei were counterstained
with 6-diamidino-2-phenylindole dihydrochloride hydrate
(DAPI). Images were obtained with a Nikon Eclipse 80i
fluorescence microscope and Meta Morph imaging series
system. The intensity of staining and the positive signal
coverage area were quantified with ImageJ (NIH).Statistics
A student’s t-test (two-tailed, unpaired) was used to cal-
culate P values between groups where indicated.Figure 3 In vivo efficacy of sEphB4-HSA combined with
Bevacizumab. 211H tumors were treated with sEphB4-HSA alone
(20 mg/kg, 3 times a week), Bevacizumab alone (20 mg/kg, 3 times
a week), or sEphB4-HSA combined with Bevacizumab. PBS was used
as control. Treatment in single-agent groups and control group was
continued for 21 days, whereas treatment in the combination group
was continued for 42 days until complete tumor regression. *, P<0.05;
**, P<0.02; ***, P<0.01. Error bars indicate standard error of mean.Results and discussion
EphB4 overexpression in MPM tumors
39 human MPM tumor samples consisting of 27 epithe-
lioid, 8 sarcomatoid, 2 papillary epithelioid, 1 mixed, and
1 desmoplastic subtypes were studied for EphB4 expres-
sion by immunohistochemistry. 85% of epithelioid, 38%
of sarcomatoid, and 100% of mixed cell type were posi-
tive for EphB4 overexpression (moderate or strong stai-
ning, Figure 1A). The representative IHC pictures of
EphB4 expression in epithelioid and sarcomatoid MPM
subtypes are shown in Figure 1B. In light of personalized
therapeutics, this observation that EphB4 overexpression
is more frequent in epithelioid tissues is important
for clinical study design with therapeutic compounds
targeting EphB4 and consideration to select appropriate
cases.
The EphB4 antibody (MAb131) used for mesothelioma
tissue staining has been shown to have no cross-
reactivity to other EphB receptors [27]. To further
confirm its specificity in staining, we used it to stain
293T cells ectopically expressing EphB4 and 293T cells
transfected with empty vector. Only EphB4 overexpressing
293T cells showed signal (Figure 1C), confirming the spe-
cificity of MAb131.In vivo activity of sEphB4-HSA in a xenograft model of
malignant mesothelioma
sEphB4 is a soluble decoy of EphB4 that blocks EphB4-
Ephrin-B2 bi-directional signaling [28]. sEphB4-HSA has
full-length human serum albumin fused to the C-terminus
of sEphB4 to improve half life and delivery [14,29]. We
have previously shown that both variants of the protein
the sEphB4 alone and sEphB4-HSA have anti-tumor acti-
vities in multiple tumor models [14,28,30].
Utilizing anti-sense oligonucleotides against EphB4, we
had previously reported decreased survival of mesothe-
lioma cell lines [24]. Here, we studied the antitumor
activity of sEphB4-HSA in mesothelioma xenograft
models using the human sarcomatoid mesothelioma cell
line H2373 that has robust overexpression of EphB4.
Sarcomatoid is also a category of mesothelioma that is
the most difficult to treat. After 25 days of treatment,
mice receiving sEphB4-HSA had a 66% reduction in
tumor volume (Figure 2A, P < 0.02) compared to con-
trol group, and a 20% regression from the starting tumor
volume (P < 0.05). Tissues harvested at the conclusion
of the study showed reduced vessel density (18% of con-
trol; Figure 2B), cell proliferative index (36% of control;
Figure 2B), and increased apoptosis (19-fold increase over
control; Figure 2C). Thus, blockade of EphB4 activation
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liferation and also induced mesothelioma cell apoptosis
in vivo.
The PI3K pathway is a major pathway downstream of
EphB4 and a critical pathway in mesothelioma [20,31]. It
is also known that activation of the PI3K pathway in-
creases EphB4 levels [15], thus establishing a positive
feedback loop. Here, sEphB4-HSA-treated MPM tumors
showed marked decreases in PI3K signaling measured
by the downstream levels of phophorylated Akt (Ser473)
and phosphorylated ribosomal protein S6 (Ser235/
Ser236; Figure 2D). sEphB4-HSA also reduced phos-
phorylation of Src, which signals downstream of Ephrin-
B2 activation [25,26]. Activated Src induces Bcl-xL and
Mcl-1 [32]; thus, inhibition of Src activation may con-
tribute to the sEphB4-HSA-induced apoptosis seen here.
In addition, inhibition of phosphorylation of Akt, S6,
and Src was observed at the end of the 25-day treat-
ment, suggesting that the treatment did not trigger a
rebound effect.Figure 4 Combinatorial effects of sEphB4-HSA and Bevacizumab on t
Figure 3 for one week. Tumors were then harvested for immunofluorescen
Pericyte recruitment to tumor vessel was evaluated by colocalization of NG
proliferative index was evaluated by Ki67 staining and apoptosis was assess
used for quantification and statistical analysis. *, P<0.05; **, P<0.01; ***, P<0Combination of sEphB4-HSA and VEGF antibody
We have shown previously that VEGF and VEGFRs are
expressed in MPM, which is one of the few tumors
that utilizes VEGF as an autocrine growth factor [33].
sEphB4-HSA has been shown to markedly inhibit tumor
angiogenesis leading to elevated tumor VEGF levels [14],
suggesting that the combination of sEphB4-HSA with
VEGF inhibition may lead to enhanced anti-angiogenesis
and antitumor activity. We thus combined sEphB4-HSA
and the VEGF-neutralizing antibody Bevacizumab in a
xenograft study. In light of the H2373 data, we tested
another mesothelioma cell line, 211H. This cell line also
overexpresses EphB4 and was derived from a patient
with biphasic histology, a hard to treat category of meso-
thelioma [24]. Both agents were highly active alone (71%
and 77% reduction in tumor volume at day 21 compared
to control group for Bevacizumab and sEphB4-HSA, res-
pectively), while combination therapy led to complete
regression of the established tumor after 38 days of
treatment (Figure 3), suggesting that this combinationumor vasculature and tumor cells. 211H tumors were treated as in
ce analysis. Tumor vessel density was evaluated by CD31 staining.
2-positive pericytes and CD31-positive endothelial cells. Cell
ed with TUNEL staining. At least 4 images from each analysis were
.002. Error bars indicate standard error of mean.
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regimen.
Since tumors went to complete remission after com-
binatorial treatment of sEphB4-HSA and Bevacizumab,
we had no tumor tissues for analysis. Therefore, we
performed a one-week treatment of 211H tumors to
analyze the mechanism of the combinatorial effects of
sEphB4-HSA and Bevacizumab (Figure 4). After one week
treatment, sEphB4-HSA and Bevacizumab each alone re-
duced vessel density (P < 0.01 and P < 0.05, respectively).
sEphB4-HSA had much greater inhibition of tumor vessel
density than Bevacizumab, which is consistent with our
previous study in Kaposi’s Sarcoma [14]. However,
tumor growth inhibitions after 3 weeks of treatment with
sEphB4-HSA and Bevacizumab were similar (Figure 3).
This is very likely due to Bevacizumab’s effects on tumor
cells directly - mesothelioma is one of only few tumor
types that express VEGFR2, produce VEGF and thus have
an autocrine loop [33].
We also observed that vessels in Bevacizumab-treated
tumors appeared normal in caliber while sEphB4-HSA
led to not only significantly reduced vessel density, but
also markedly reduced vessel length, vessel caliber, and
pericyte recruitment (measured by co-localization of
NG2-positive pericytes and CD31-positive endothelial
cell; P < 0.002) compared to Bevacizumab treatment.
Ephrin-B2 is strongly expressed on tumor vessels and
is necessary for maintaining tumor vasculature. The
EphB4-Ephrin-B2 inhibitor sEphB4-HSA prevents EphB4-
induced Ephrin-B2 activation in MPM tumor cells. This
blockade has two outcomes on tumor vasculature. First,
since Ephrin-B2 binds directly to VEGFRs and its activa-
tion is required for VEGFR activation [11,13], EphB4-
Ephrin-B2 blockade will inhibit VEGF-induced signaling.
Second, pericyte recruitment and vessel maturation will
be impaired because Ephrin-B2 is also expressed on peri-
cytes and is necessary for these processes. sEphB4-HSA
treatment thus leads to not only fewer but also less mature
tumor vessels. When sEphB4-HSA and Bevacizumab were
combined, vessel density is further decreased (P < 0.01
compared to Bevacizumab alone), along with diminished
pericyte recruitment (P < 0.05 compared to Bevacizumab
alone). This enhanced anti-angiogenesis activity combined
with direct antitumor activity led to more significantly re-
duced proliferation (Ki67 staining, P < 0.002 compared to
Bevacizumab alone) and increased apoptosis (TUNEL
staining, P < 0.05 compared to Bevacizumab alone) than
either single agent alone (Figure 4). This may explain the
complete regression seen in the long-term combinatorial
treatment.
Conclusions
In this study, we found that EphB4 is highly expressed in
MPM, especially in epithelioid subtype, and represents apotential therapeutic target. We also found that the
EphB4-Ephrin-B2 inhibitor sEphB4-HSA, alone or com-
bined with the anti-VEGF antibody Bevacizumab was
highly active in inhibiting mesothelioma growth in
xenograft models. sEphB4-HSA is currently in a clinical
Phase 1 trial (ClinicalTrials.gov Identifier: NCT01642342).
The data presented here suggest that mesothelioma
should be a target disease in clinical investigation of
this novel therapy, and the combination of sEphB4-
HSA and Bevacizumab should undergo further clini-
cal investigation.
Competing interests
Kranthi Naga and Valery Krasnoperov are employees of VasGene
Therapeutics Inc.
Authors’ contributions
RL and YZ carried out the xenograft studies and immunoanalysis of tumor
tissues. BF performed immunoanalysis of human MPM tissues. KN and VK
produced EphB4 antibody and sEphB4-HSA for this study. RS, PSG, and VK
participated in the design of the study. RL, BF, RS, PSG, and VK drafted the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was in part supported by SBIR grants (1R43 CA 171538-01 and
1R43 CA 168158-01) to VK, mesothelioma Foundation of America to PSG and
DOD to RS.
Author details
1School of Medicine, University of Southern California, 1441 Eastlake Avenue,
Los Angeles, CA 90033, USA. 2Pritzker School of Medicine, University of
Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USA. 3VasGene
Therapeutics Inc, 1929 Zonal Avenue, Los Angeles, CA 90033, USA.
Received: 11 January 2013 Accepted: 28 May 2013
Published: 30 May 2013
References
1. Carbone M, Kratzke RA, Testa JR: The pathogenesis of mesothelioma.
Semin Oncol 2002, 29(1):2–17.
2. Chen SE, Pace MB: Malignant pleural mesothelioma. Am J Health Syst
Pharm 2012, 69(5):377–385.
3. Cao C, Yan TD, Bannon PG, McCaughan BC: Summary of prognostic
factors and patient selection for extrapleural pneumonectomy in the
treatment of malignant pleural mesothelioma. Ann Surg Oncol 2011,
18(10):2973–2979.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P,
Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III
study of pemetrexed in combination with cisplatin versus cisplatin alone
in patients with malignant pleural mesothelioma. J Clin Oncol 2003,
21(14):2636–2644.
5. Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL:
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab
in patients with advanced malignant mesothelioma. Lung Cancer 2012,
77(3):567–571.
6. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Janne PA,
Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd,
Vogelzang NJ, Chen HX, Stadler WM, Vokes EE: Multicenter, double-blind,
placebo-controlled, randomized phase II trial of gemcitabine/cisplatin
plus bevacizumab or placebo in patients with malignant mesothelioma.
J Clin Oncol 2012, 30(20):2509–2515.
7. Gerety SS, Anderson DJ: Cardiovascular ephrinB2 function is essential for
embryonic angiogenesis. Development 2002, 129(6):1397–1410.
8. Gerety SS, Wang HU, Chen ZF, Anderson DJ: Symmetrical mutant
phenotypes of the receptor EphB4 and its specific transmembrane
ligand ephrin-B2 in cardiovascular development. Mol Cell 1999,
4(3):403–414.
Liu et al. BMC Cancer 2013, 13:269 Page 7 of 7
http://www.biomedcentral.com/1471-2407/13/2699. Shin D, Garcia-Cardena G, Hayashi S, Gerety S, Asahara T, Stavrakis G, Isner J,
Folkman J, Gimbrone MA Jr, Anderson DJ: Expression of ephrinB2
identifies a stable genetic difference between arterial and venous
vascular smooth muscle as well as endothelial cells, and marks subsets
of microvessels at sites of adult neovascularization. Dev Biol 2001,
230(2):139–150.
10. Salvucci O, Maric D, Economopoulou M, Sakakibara S, Merlin S, Follenzi A,
Tosato G: EphrinB reverse signaling contributes to endothelial and mural
cell assembly into vascular structures. Blood 2009, 114(8):1707–1716.
11. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T,
Acker-Palmer A: Ephrin-B2 regulates VEGFR2 function in developmental
and tumour angiogenesis. Nature 2010, 465(7297):487–491.
12. Abengozar MA, de Frutos S, Ferreiro S, Soriano J, Perez-Martinez M, Olmeda
D, Marenchino M, Canamero M, Ortega S, Megias D, Rodriguez A, Martinez-
Torrecuadrada JL: Blocking ephrinB2 with highly specific antibodies
inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood
2012, 119(19):4565–4576.
13. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara
A, Adams S, Davy A, Deutsch U, Luthi U, Barberis A, Benjamin LE, Makinen T,
Nobes CD, Adams RH: Ephrin-B2 controls VEGF-induced angiogenesis and
lymphangiogenesis. Nature 2010, 465(7297):483–486.
14. Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke
AP, Gupta S, Kumar SR, Gill PS: The role of Ephs, Ephrins, and growth
factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood
2009, 113(1):254–263.
15. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J,
Kumar NG, Hawes D, Press MF, Weaver FA, Gill PS: Receptor tyrosine
kinase EphB4 is a survival factor in breast cancer. Am J Pathol 2006,
169(1):279–293.
16. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI,
Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP,
Zhong C, Broek D, Roy-Burman P, Gill PS: EphB4 expression and biological
significance in prostate cancer. Cancer Res 2005, 65(11):4623–4632.
17. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings
N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS: The
receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer,
provides survival signals and predicts poor outcome. Br J Cancer 2007,
96(7):1083–1091.
18. Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM: Expression of
Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 2004, 10(1):26–33.
19. Lee YC, Perren JR, Douglas EL, Raynor MP, Bartley MA, Bardy PG,
Stephenson SA: Investigation of the expression of the EphB4 receptor
tyrosine kinase in prostate carcinoma. BMC Cancer 2005, 5:119.
20. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM,
Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM,
Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G,
Gill PS, Sood AK: Converging evidence for efficacy from parallel EphB4-
targeted approaches in ovarian carcinoma. Mol Cancer Ther 2010,
9(8):2377–2388.
21. Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK,
Zozulya S, Singh J, Xia G, Broek D, Schonthal AH, Gill PS: EphB4 provides
survival advantage to squamous cell carcinoma of the head and neck.
Int J Cancer 2006, 119(6):1236–1248.
22. Sinha UK, Mazhar K, Chinn SB, Dhillon VK, Liu L, Masood R, Rice DH, Gill PS:
The association between elevated EphB4 expression, smoking status,
and advanced-stage disease in patients with head and neck squamous
cell carcinoma. Arch Otolaryngol Head Neck Surg 2006, 132(10):1053–1059.
23. Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R,
Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti
R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC,
Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R:
Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal
Cancers. Cancer Res 2013, 73(1):184–194.
24. Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy
R, Krasnoperov V, Gill PS: Up-regulation of EphB4 in mesothelioma and its
biological significance. Clin Cancer Res 2005, 11(12):4305–4315.
25. Georgakopoulos A, Litterst C, Ghersi E, Baki L, Xu C, Serban G, Robakis NK:
Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-
induced Src phosphorylation and signaling. EMBO J 2006, 25(6):1242–1252.
26. Palmer A, Zimmer M, Erdmann KS, Eulenburg V, Porthin A, Heumann R,
Deutsch U, Klein R: EphrinB phosphorylation and reverse signaling:regulation by Src kinases and PTP-BL phosphatase. Mol Cell 2002,
9(4):725–737.
27. Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS:
Novel EphB4 Monoclonal Antibodies Modulate Angiogenesis and Inhibit
Tumor Growth. Am J Pathol 2010, 176(4):2029–2038.
28. Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, Zozulya S, Gill PS:
The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-
EphrinB2 interaction, modulates angiogenesis, and inhibits tumor
growth. Blood 2006, 107(6):2330–2338.
29. Shi S, Liu J, Joshi SB, Krasnoperov V, Gill P, Middaugh CR, Volkin DB:
Biophysical characterization and stabilization of the recombinant
albumin fusion protein sEphB4-HSA. J Pharm Sci 2012, 101(6):1969–1984.
30. Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M,
Krasnoperov V, Gill PS, Duarte A: Combination of Dll4/Notch and Ephrin-
B2/EphB4 targeted therapy is highly effective in disrupting tumor
angiogenesis. BMC Cancer 2010, 10(1):641.
31. Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y,
Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida T, Sekido Y: Activation of
the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med
Report 2009, 2(2):181–188.
32. Zhao W, Zhang T, Qu B, Wu X, Zhu X, Meng F, Gu Y, Shu Y, Shen Y, Sun Y,
Xu Q: Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-
mediated STAT3 phosphorylation. Anticancer Drugs 2011, 22(1):79–88.
33. Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS: Malignant
mesothelioma growth inhibition by agents that target the VEGF and
VEGF-C autocrine loops. Int J Cancer 2003, 104(5):603–610.
doi:10.1186/1471-2407-13-269
Cite this article as: Liu et al.: EphB4 as a therapeutic target in
mesothelioma. BMC Cancer 2013 13:269.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
